These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 36275803)

  • 1. Differential retention of adalimumab and etanercept biosimilars compared to originator treatments: Results of a retrospective French multicenter study.
    Larid G; Baudens G; Dandurand A; Coquerelle P; Goeb V; Guyot MH; Marguerie L; Maury F; Veillard E; Houvenagel E; Salmon JH; Flipo RM; Gervais E
    Front Med (Lausanne); 2022; 9():989514. PubMed ID: 36275803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rheumatoid arthritis treated with 6-months of first-line biologic or biosimilar therapy: an updated systematic review and network meta-analysis.
    Simpson EL; Ren S; Hock ES; Stevens JW; Binard A; Pers YM; Archer R; Paisley S; Stevenson MD; Herpin C; Ghabri S
    Int J Technol Assess Health Care; 2019 Jan; 35(1):36-44. PubMed ID: 30722803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness and safety of a biosimilar-to-biosimilar switch of the TNF inhibitor etanercept in patients with chronic inflammatory rheumatic diseases.
    Kiltz U; Tsiami S; Baraliakos X; Andreica I; Kiefer D; Braun J
    Ther Adv Musculoskelet Dis; 2022; 14():1759720X221119593. PubMed ID: 36051634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retention rates of adalimumab, etanercept, and infliximab as first- or second-line biotherapies for spondyloarthritis patients in daily practice in Auvergne (France).
    Soubrier M; Pereira B; Fan A; Frayssac T; Couderc M; Malochet-Guinamand S; Mathieu S; Tatar Z; Tournadre A; Dubost JJ
    Int J Rheum Dis; 2018 Nov; 21(11):1986-1992. PubMed ID: 30168265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retention rate of subcutaneous TNF inhibitors in axial spondyloarthritis in a multicentre study from the RIC-FRANCE network.
    Larid G; Baudens G; Tiemdjo-Djimaffo G; Coquerelle P; Goeb V; Guyot MH; Marguerie L; Maury F; Veillard E; Houvenagel E; Salmon JH; Flipo RM; Gervais E
    Sci Rep; 2024 Jan; 14(1):1374. PubMed ID: 38228719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and retention rate of adalimumab in rheumatoid arthritis and psoriatic arthritis patients after first-line etanercept failure: the FEARLESS cohort.
    Favalli EG; Becciolini A; Carletto A; Conti F; Amato G; Fusaro E; Quartuccio L; Egan CG; Lo Monaco A; Benucci M; Salaffi F; Semeraro A; Parisi S; Ceccarelli F; Piazza I; Foti R
    Rheumatol Int; 2020 Feb; 40(2):263-272. PubMed ID: 31435754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment retention of infliximab and etanercept originators versus their corresponding biosimilars: Nordic collaborative observational study of 2334 biologics naïve patients with spondyloarthritis.
    Lindström U; Glintborg B; Di Giuseppe D; Nordström D; Aarrestad Provan S; Gudbjornsson B; Askling J; Lund Hetland M; Aaltonen K; Krogh NS; Geirsson AJ; Jacobsson LTH
    RMD Open; 2019; 5(2):e001079. PubMed ID: 31749988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retention rates of adalimumab, etanercept and infliximab as first-line biotherapy agent for rheumatoid arthritis patients in daily practice - Auvergne experience.
    Soubrier M; Pereira B; Frayssac T; Fan A; Couderc M; Malochet-Guinamand S; Mathieu S; Tatar Z; Tournadre A; Dubost JJ
    Int J Rheum Dis; 2018 Nov; 21(11):1924-1932. PubMed ID: 28901727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Era of biosimilars in rheumatology: reshaping the healthcare environment.
    Smolen JS; Goncalves J; Quinn M; Benedetti F; Lee JY
    RMD Open; 2019; 5(1):e000900. PubMed ID: 31245050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient knowledge about biosimilars and satisfaction with the education provided by rheumatologists or nurse specialists in a biosimilar multiswitch scenario - The perception study.
    Gall S; Kiltz U; Kobylinski T; Andreica I; Vaupel K; Waldecker C; Baraliakos X; Braun J
    Semin Arthritis Rheum; 2022 Dec; 57():152119. PubMed ID: 36341778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of switching from reference adalimumab to SB5 in a real-life cohort of inflammatory rheumatic joint diseases.
    Bruni C; Bitti R; Nacci F; Cometi L; Tofani L; Bartoli F; Fiori G; Matucci-Cerinic M
    Clin Rheumatol; 2021 Jan; 40(1):85-91. PubMed ID: 32514676
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-Term Survival of Subcutaneous Biosimilar Tumor Necrosis Factor Inhibitors Compared to Originators: Results From a Multicenter Prospective Registry.
    Martínez-Vidal MP; Fernández-Carballido C; Otero-Varela L; Ruiz FJM; Pérez-Vera Y; Arija SM; Fernández CC; Jovaní V; Expósito L; Lario BÁ; García-González J; Sánchez-Alonso F; Castrejón I
    J Rheumatol; 2024 Sep; 51(9):877-883. PubMed ID: 38825358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eight-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Spondyloarthritis: A Multicenter Retrospective Analysis.
    Favalli EG; Selmi C; Becciolini A; Biggioggero M; Ariani A; Santilli D; Fusaro E; Parisi S; Massarotti M; Marchesoni A; Meroni PL
    Arthritis Care Res (Hoboken); 2017 Jun; 69(6):867-874. PubMed ID: 27696735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world use of an etanercept biosimilar including selective
    Cooksey R; Brophy S; Kennedy J; Seaborne M; Choy E
    Rheumatol Adv Pract; 2022; 6(2):rkac056. PubMed ID: 35910710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose Escalation and Co-therapy Intensification Between Etanercept, Adalimumab, and Infliximab: The CADURA Study.
    Thorne C; Boire G; Chow A; Garces K; Liu F; Poulin-Costello M; Walker V; Haraoui B
    Open Rheumatol J; 2017; 11():123-135. PubMed ID: 29296125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment Patterns, Direct Cost of Biologics, and Direct Medical Costs for Rheumatoid Arthritis Patients: A Real-world Analysis of Nationwide Japanese Claims Data.
    Sugiyama N; Kawahito Y; Fujii T; Atsumi T; Murata T; Morishima Y; Fukuma Y
    Clin Ther; 2016 Jun; 38(6):1359-1375.e1. PubMed ID: 27101816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug retention rates of second biologic agents after switching from tumor necrosis factor inhibitors for rheumatoid arthritis in Japanese patients on low-dose methotrexate or without methotrexate.
    Kobayakawa T; Kojima T; Takahashi N; Hayashi M; Yabe Y; Kaneko A; Shioura T; Saito K; Hirano Y; Kanayama Y; Miyake H; Asai N; Funahashi K; Hirabara S; Hanabayashi M; Asai S; Ishiguro N
    Mod Rheumatol; 2015 Mar; 25(2):251-6. PubMed ID: 25211402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rate of serious infections in spondyloarthropathy patients treated with anti-tumour necrosis factor drugs: a survey from the Italian registry GISEA.
    Atzeni F; Sarzi-Puttini P; Sebastiani M; Panetta V; Salaffi F; Iannone F; Carletto A; Foti R; Gremese E; Govoni M; Marchesoni A; Favalli E; Gorla R; Ramonda R; Ferraccioli G; Lapadula G;
    Clin Exp Rheumatol; 2019; 37(4):649-655. PubMed ID: 30767865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biosimilars for the treatment of psoriatic arthritis.
    Cantini F; Benucci M; Li Gobbi F; Franchi G; Niccoli L
    Expert Rev Clin Immunol; 2019 Nov; 15(11):1195-1203. PubMed ID: 31625769
    [No Abstract]   [Full Text] [Related]  

  • 20. Calprotectin and TNF trough serum levels identify power Doppler ultrasound synovitis in rheumatoid arthritis and psoriatic arthritis patients in remission or with low disease activity.
    Inciarte-Mundo J; Ramirez J; Hernández MV; Ruiz-Esquide V; Cuervo A; Cabrera-Villalba SR; Pascal M; Yagüe J; Cañete JD; Sanmarti R
    Arthritis Res Ther; 2016 Jul; 18(1):160. PubMed ID: 27391315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.